Marrow Transplant Technique May Help Blood Cancer Patients
Posted on: Wednesday, 28 September 2005, 18:00 CDT
WEDNESDAY, Sept. 28 (HealthDay News) -- A more focused approach to bone marrow transplant in patients with blood cancers dramatically lowered the incidence of graft versus host disease (GVHD) -- a potentially deadly complication of the procedure -- in a small group of patients, researchers report.
The approach has the potential to provide an easier alternative for people with leukemia, lymphoma and other related cancers, especially people over the age of 50, who typically have trouble withstanding conventional bone marrow transplantation procedures.
The findings appear in the Sept. 29 issue of the New England Journal of Medicine.
"We need replication in other studies but, if it is verified, it means there would be another approach to conditioning a patient that would greatly minimize acute GVHD but lead to the same beneficial effects," said Dr. Marshall Lichtman, executive vice president of research and medical programs for the Leukemia & Lymphoma Society.
Bone marrow transplants can cure some cases of leukemia, lymphoma and related blood cancers. The procedure is a severe one, however, and involves knocking out the patient's existing bone marrow with chemotherapy and/or radiation, then replacing the diseased blood stem cells with healthy stem cells from a donor.
People over the age of 50, in particular, have a hard time tolerating the standard form of transplantation, which can cause GVHD in about 50 percent of cases. In GVHD, the donor's immune cells attack the patient's body, causing intense diarrhea and severe rashes, among other things.
Recently, researchers have managed to show that, in mice, a less severe procedure had good results with fewer side effects.
Instead of receiving the blanket chemotherapy and radiation typical before bone marrow transplantation, the mice received radiation only to the lymph-node-bearing areas. They also received antithymocyte globulin, an immunosuppressive agent that destroys immune T-cells.
However, instead of destroying all of the patient's immune T-cells, this treatment selectively depleted just certain subsets of T-cells and allowed others, namely regulatory T-cells, to survive. The researchers explain that regulatory T-cells can hold attacking immune cells at bay.
"The regulatory T-cells are there in a high enough ratio to be able to shape and modify the donor immune cells to protect against GVHD, but still allow donor T-cells to mediate a graft anti-tumor effect," said study author Dr. Robert Lowsky, an assistant professor of medicine at Stanford University School of Medicine.
In other words, the donor T-cells attacked the tumor, but nothing else.
In the mouse study, regulatory T-cells went from a comprising 1 percent of total T-cells to more than 90 percent. The mice also had a significant reduction in acute GVHD.
The current study replicated that procedure in humans.
Thirty-seven patients with lymphoid malignant diseases or acute leukemia underwent an experimental conditioning regimen starting with radiation to the lymph nodes only plus antithymocyte globulin, followed by a bone marrow transplant.
Only two of the patients developed acute GVHD and only one of those had "clinically significant" disease. In addition, patients with lymphoid malignant diseases who were in partial remission went into a complete remission.
Rates of chronic GVHD, a less serious form of the disorder, were no different, the researchers note.
"What these folks are saying is that if you use this conditioning regimen, you can get very good results and you eliminate or you greatly minimize acute GVHD," Lichtman said. "You keep the good effects while reducing the bad."
An accompanying editorial pointed out some caveats, however, including the small number of patients involved in the study and the inability to discern exactly what was responsible for the low incidence of GVHD.
The follow-up time was also not particularly long (seven months to three years), Lichtman added.
Lowsky and colleagues say they are making plans to study the procedure in a larger number of patients.
"The findings were pretty striking," Lichtman. "It would be a step forward in making transplant more accessible to more people, especially older people, and reducing the morbidity and mortality from acute GVHD."
More information
The National Marrow Donation Program has more on transplants.
SOURCES: Robert Lowsky, M.D., assistant professor, medicine, Stanford University School of Medicine, Stanford, Calif.; Marshall Lichtman, M.D., executive vice president, research and medical programs, Leukemia & Lymphoma Society, White Plains, N.Y.; September 29, 2005 New England Journal of Medicine~BLOO~~-LEU~~IMMN~~ORGT~
Source: HealthSCOUT
Related Articles
- Cephalon Provides Clinical Update on Lestaurtinib in Relapsed Acute Myelogenous Leukemia
- Micromet's Blinatumomab Achieves Primary Endpoint in Phase 2 Study with Acute Lymphoblastic Leukemia Patients
- Celator(R) Pharmaceuticals Enrolls First Patient in Its Phase 2 Study of CPX-351 in Acute Myeloid Leukemia in First Relapse
- Gemin X Pan Bcl-2 Inhibitor Obatoclax Demonstrates Biological and Clinical Activity in Heavily Pre-Treated Patients With Advanced Chronic Lymphocytic Leukemia
- Xanthus' Xanafide Bypasses Multi-Drug Resistance Proteins in Acute Myeloid Leukemia
- Xanthus Initiates Pivotal Phase 3 Trial of Xanafide in Secondary Acute Myeloid Leukemia
- Xanthus Completes Special Protocol Assessment With FDA for Phase 3 Registration Trial of Xanafide in Patients With Secondary Acute Myeloid Leukemia
- Hana Biosciences Receives Orphan Drug Designation for Talotrexin (PT-523), For the Treatment of Acute Lymphoblastic Leukemia
- Clofarabine European Study Confirms Efficacy in Pediatric Patients With Acute Lymphoblastic Leukemia; Study Update at American Society of Hematology
- Advances in Understanding the Biology and Genetics of Acute Myelocytic Leukemia
 |
 |
User Comments (0)
RSS Feeds